First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 781 000 KRW
Updated: May 16, 2024

Gross Margin
Samsung Biologics Co Ltd

48.8%
Current
45%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.8%
=
Gross Profit
1.8T
/
Revenue
3.7T

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
49%
US
Thermo Fisher Scientific Inc
NYSE:TMO
231.7B USD
40%
US
Danaher Corp
NYSE:DHR
195.1B USD
58%
US
Agilent Technologies Inc
NYSE:A
45.2B USD
51%
US
IQVIA Holdings Inc
NYSE:IQV
42.4B USD
35%
CH
Lonza Group AG
SIX:LONN
38.3B CHF
36%
US
Mettler-Toledo International Inc
NYSE:MTD
32.5B USD
59%
IE
ICON PLC
NASDAQ:ICLR
26.6B USD
30%
US
West Pharmaceutical Services Inc
NYSE:WST
25.6B USD
37%
FR
Sartorius Stedim Biotech SA
PAR:DIM
19.8B EUR
43%
US
Waters Corp
NYSE:WAT
21.5B USD
60%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 55.6T KRW
Gross Margin
49%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 231.7B USD
Gross Margin
40%
Danaher Corp
NYSE:DHR
Country US
Market Cap 195.1B USD
Gross Margin
58%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 45.2B USD
Gross Margin
51%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 42.4B USD
Gross Margin
35%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 38.3B CHF
Gross Margin
36%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 32.5B USD
Gross Margin
59%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.6B USD
Gross Margin
30%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 25.6B USD
Gross Margin
37%
Sartorius Stedim Biotech SA
PAR:DIM
Country FR
Market Cap 19.8B EUR
Gross Margin
43%
Waters Corp
NYSE:WAT
Country US
Market Cap 21.5B USD
Gross Margin
60%

Profitability Report

View the profitability report to see the full profitability analysis for Samsung Biologics Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.8%
=
Gross Profit
1.8T
/
Revenue
3.7T
What is the Gross Margin of Samsung Biologics Co Ltd?

Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Gross Margin of 48.8%.

ALPHA SPREAD
Join more than 137,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.